Boston Biomedical is an R&D stage biopharmaceutical company working to develop the next generation of targeted cancer therapeutics.
Before a new drug hits the market, it must first pass through three phases of clinical trials. Pat Andrews and her team at Boston Biomedical specialize in evaluating whether or not compounds merit further study. One of the company’s greatest challenges is finding the best people to talk to in an efficient, effective way during the drug discovery process. Boston Biomedical cites GLG and the GLG Institute as invaluable tools for unlocking new insights from a wide-range of executives, as they continue to face their most pressing learning challenges.